Accounting for Global Health - Understanding Funding Opportunities  

1:45 PM - 2:45 PM
Room 146A

This panel will shed light on trends in global health funding and philanthropy. It will answer the questions: What funding is currently available? How do companies access it? In addition to direct funding, what other incentives are available for product development?

Panelists:

  • Moderator: Yves Ribeill, CEO, SCYNEXIS
  • Erin Hogan, Vice President, Senior Philanthropic Advisor, JP Morgan
  • Mary Moran, CEO, Policy Cures
  • Andrew Robertson, Chief Policy Officer, BIO Ventures for Global Health

Who's Who


Hogan Erin Hogan - Erin Hogan, Vice President, serves as a senior philanthropic advisor for individuals, families, private foundations and charitable trust clients of J.P. Morgan Private Bank.  Erin specializes in giving programs in the areas of health care, medical research, international relief, k-12 and higher education and social services. 

Before joining J.P. Morgan, Erin was a research manager at Columbia University’s Mailman School of Public Health where she supervised research programs in emergency preparedness, infectious disease control and occupational health and safety.  Prior to that, Erin worked for a Washington, D.C. consulting firm on a variety of public health and environmental safety projects for government agencies such as the U.S. Environmental Protection Agency and the Federal Emergency Management Agency. 

Erin is a former paramedic and has volunteered with numerous public health and education organizations.  She currently serves as the vice chair for the Donors’ Education Collaborative of New York City and as an advisor for the GAVI Campaign.  Erin is a member of Grantmakers in Health, Grantmakers for Education and the Alumni Board for the Mailman School of Public Health at Columbia University.  Erin has a Masters of Public Health degree from Columbia University and a BS in Health Sciences from The George Washington University.

   
  Mary Moran - Dr. Moran, Director of Policy Cures, has over 20 years experience in health policy and practice, including 10 years specialising in neglected disease policy. She has conducted projects for a wide range of public and multilateral health organisations with a focus on policy solutions for emerging issues related to neglected disease R&D. In 2004, Mary founded the research group that became Policy Cures at the London School of Economics & Political Science, later transferring it to the George Institute for International Health in Sydney.

Prior to forming the group, she worked for over a decade in Emergency Medicine; was a diplomat and policy analyst with the Australian Department of Foreign Affairs & Trade; Director of Medecins Sans Frontieres Access to Essential Medicines Campaign in Australia; and a Europe-based policy advocate with MSF on issues relating to access to medicines for neglected patients. Mary is an Honorary Senior Lecturer at the London School of Hygiene and Tropical Medicine, and an Expert Adviser to the World Health Organisation, European Commission, European and Developing Countries Clinical Trials Partnership, Global Alliance for Vaccines and Immunisation (GAVI), OECD and the Wellcome Trust.
   
Ribeill Yves Ribeill - Dr. Yves Ribeill is the President & CEO of SCYNEXIS, Inc.  Dr. Ribeill was the Director of Chemistry for Insecticide and Animal Health Research at Rhone-Poulenc Agricultural Products Company facility in Research Triangle Park, North Carolina.  He held this position from January 1998 to July 1, 2000.

Before joining the agrochemical sector Dr. Ribeill held various positions during his 14 years in the pharmaceutical sector of Rhone-Poulenc including group leader in Discovery Chemistry for Antiviral Research and later in the Central Nervous System Group in France. He then became group leader in the Cardiovascular Group in England. Upon his return to France he was appointed Director of Chemistry for the Anti-Infective Group.  Dr. Ribeill was involved in all phases of the drug discovery and development effort that culminated in the FDA approval of the antibacterial Synercid in 1999.

Dr. Ribeill received his Ph.D. from the University of Montpellier (France) after conducting research on the development of new synthetic methodologies utilizing phosphorus compounds. He is the author of more than 26 publications and 12 patents.  Dr. Ribeill is an expert-advisor to the French Government for drug research investment and member of the Medicines Malaria Venture Expert Scientific Advisory committee at the World Health Organization in Geneva.  He is a member of the Royal Society of Chemistry in England and of the French Society of Chemistry. 
   
Robertson Andrew Robertson - Andrew S. Robertson joined BIO Ventures for Global Health (BVGH) as Chief Policy Officer in September 2010. He brings with him an expertise in innovation policy, and carries a diverse background centered on science policy and neglected disease research.

Before joining BVGH, Dr. Robertson was a graduate researcher at the University of California, Berkeley, where he focused on issues regarding synthetic biology, personalized medicine, and drug development within neglected disease markets. Prior to this, Dr. Robertson served as an International Health Officer and Science Advisor at the U.S. Department of Health and Human Services (HHS), Office of the Secretary. At HHS, his portfolio included issues concerning global health, biodefense, and biosecurity, with a particular focus on pandemic influenza. Dr. Robertson held a faculty research post at the Wellcome Trust Sanger Institute in Cambridge, UK, where he focused on immunology and protease inhibition.

In addition to his professional activities, Dr. Robertson is a Trustee of the Gates Cambridge Scholarship, serves as Co-Chair of the American Bar Association’s Committee for the Rights and Responsibilities of Scientists, and was a AAAS Science & Technology Policy Fellow. He received his JD from the University of California, Berkeley, School of Law (Certificate in Science & Technology Law), and his PhD in genetics from the University of Cambridge, where he was a Gates Cambridge Scholar.